Little Melvyn (ed.) Recombinant Antibodies for Immunotherapy

Cambridge University Press, 2009. — 444 p.Recombinant Antibodies for Immunotherapy provides a comprehensive overview of the field of monoclonal antibodies (mAbs), a market that has grown tremendously in recent years. Twenty-five articles by experienced and innovative authors cover the isolation of specific human mAbs, humanization, immunogenicity, technologies for improving efficacy, 'arming' mAbs, novel alternative Ab constructs, increasing half-lives, alternative concepts employing non-immunoglobulin scaffolds, novel therapeutic approaches, a market analysis of therapeutic mAbs, and future developments in the field. The concepts and technologies are illustrated by examples of recombinant antibodies being used in the clinic or in development. This book will appeal to both newcomers and experienced scientists in the field, biology and biotechnology students, research and development departments in the pharmaceutical industry, medical researchers, clinicians, and biotechnology investors.Foreword by Sir Gregory Winter.Humanized Antibodies.
Humanization of Recombinant Antibodies.
Jose´ W. Saldanha.
Immunogenicity Assessment of Antibody Therapeutics.
Philippe Stas, Jurgen Pletinckx, Yannick Gansemans, and Ignace Lasters.
In Vitro Screening for Antibody Immunogenicity.
Frank J. Carr and Matthew P. Baker.
Generation and Screening of Antibody Libraries.
Antibody Libraries from Naı¨ve V Gene Sources.
Gerald Beste and David Lowe.
Antibodies from IgM Libraries.
Stefan Knackmuss and Vera Molkenthin.
Generation and Screening of the Synthetic Human Combinatorial.
Antibody Library HuCAL GOLD.
Ingo M. Klagge.
Transgenic Human Antibody Repertories.
Therapeutic Antibodies from XenoMouse Transgenic Mice.
Aya Jakobovits.
VelocImmune: Immunoglobulin Variable Region Humanized Mice.
Andrew Murphy.
Antibody Effector Function.
Mechanisms of Tumor Cell Killing by Therapeutic Antibodies.
Ross Stewart and Carl Webster.
Optimization of Fc Domains to Enhance Antibody Therapeutics.
Greg A. Lazar and Aaron K. Chamberlain.
Glycoengineered Therapeutic Antibodies.
Peter Bru¨nker, Peter Sondermann, and Pablo Uman˜a.
Arming Antibodies.
Monoclonal Antibodies for the Delivery of Cytotoxic Drugs.
David J. King.
Immunotherapy with Radio-immune Conjugates.
Christina A. Kousparou and Agamemnon A. Epenetos.
Immunotherapeutic Antibody Fusion Proteins.
Nigel S. Courtenay-Luck and David Jones.
Novel Antibody Formats.
Alternative Antibody Formats.
Fabrice Le Gall and Melvyn Little.
Single-Domain Antibodies.
Serge Muyldermans, Gholamreza Hassanzadeh Ghassabeh, and Dirk Saerens.
Engineering of Non-CDR Loops in Immunoglobulin Domains.
Florian Ru¨ker and Gordana Wozniak-Knopp.
Antigen-Binding Repertories of Non-Immunoglobulin Proteins.
Alternative Scaffolds: Expanding the Options of Antibodies.
Andreas Plu¨ckthun.
Prolongation of Serum Half-Life.
Polymer Fusions to Increase Antibody Half-Lives: PEGylation and Other Modifications.
Sam P. Heywood and David P. Humphreys.
Extending Antibody Fragment Half-Lives with Albumin.
Jan Terje Andersen and Inger Sandlie.
Innovative Immunotherapeutic Approaches.
A Stem Cell–Based Platform for the Discovery and Development of Antitumor Therapeutic Antibodies to Novel Targets.
Jennie P. Mather, Claudia Fieger, Tony W. Liang, Kathleen L. King, Jonathan Li, Peter Young, Claude Beltejar, Beverly Potts, Monica Licea, and Deryk Loo.
Antibody Directed Enzyme Prodrug Therapy (ADEPT).
Helen L. Lowe, Surinder K. Sharma, Kenneth D. Bagshawe, and.
Kerry A. Chester.
Immune Privilege and Tolerance – Therapeutic Antibody Approaches.
Daron Forman, Paul Ponath, Devangi Mehta, Joe Ponte, Jessica Snyder, Patricia Rao, Herman Waldmann, and.
Michael Rosenzweig.
Market Overview and Outlook.
Antibody Therapeutics: Business Achievements and Business Outlook.
Christophe Bourrilly.Color plates follow page xvi.